Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/Dex) as initial therapy for myeloma. Thirtyfour patients were enrolled. Lenalidomide was given orally 25 mg daily on days 1 to 21 of a 28-day cycle. Dexamethasone was given orally 40 mg daily on days 1 to 4, 9 to 12,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rajkumar, S. Vincent, Hayman, Suzanne R., Lacy, Martha Q., Dispenzieri, Angela, Geyer, Susan M., Kabat, Brian, Zeldenrust, Steven R., Kumar, Shaji, Greipp, Philip R., Fonseca, Rafael, Lust, John A., Russell, Stephen J., Kyle, Robert A., Witzig, Thomas E., Gertz, Morie A.
Formato: Artigo
Lenguaje:Inglês
Publicado: © 2005 by The American Society of Hematology 2005
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895238/
https://ncbi.nlm.nih.gov/pubmed/16118317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-07-2817
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares